Actinic keratoses: Past, present and future

Journal of Drugs in Dermatology

Volumn 9, Issue 5, 2010, Pages

  Fenske, Neil Alan ^a   Spencer, James ^b   Friedman, Adam ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BLUE LIGHT; CANCER RECURRENCE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CRYOSURGERY; DRUG EFFICACY; DRUG TOLERABILITY; FACE DISORDER; FIELD CANCERIZATION; FREEZE THAWING; GENE MUTATION; HEAD AND NECK DISEASE; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; INFECTION RISK; KELOID; LIGHT EMITTING DIODE; LOCAL SKIN REACTION; MALIGNANT LENTIGO; MULTIPLE CYCLE TREATMENT; PAGET SKIN DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOACTIVATION; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED LIGHT; SCALP; SCAR FORMATION; SKIN PAIN; SKIN REDNESS; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; PATHOLOGY; PHOTOCHEMOTHERAPY; PRECANCER; REVIEW; SKIN TUMOR;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA, SQUAMOUS CELL; CRYOSURGERY; DICLOFENAC; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOSIS, ACTINIC; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS;

EID: 77954513687     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ackerman BA and Mones JM. Solar (actinic) keratosis is squamous cell carcinoma Br J Dermatol. 2006;155(1):9-22. (Pubitemid 43876387)
2. Park HR, Min SK, Cho HD, et al. Expression profiles of p63, p53, survivin and hTERT in skin tumors. J Cutan Pathol. 2004;31:544-549.
3. Soufir N, Moles JP, Vilmer C, et al. P16 UV mutations in human skin epithelial tumors. Oncogene. 1999;18:5477-5481. (Pubitemid 29469236)
4. Mortier L, Marchetti P, Delaporte E, et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16 INK4a tumor suppressor. Cancer Lett. 2002;176:205-214. (Pubitemid 34139786)
5. Spencer JM, Kahn SM, Jiang W, et al. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinoma. Arch Dermatol. 1995;131:796-800.
6. Perrett CM, McGregor JM, Warwick J, et al. Treatment of posttransplant premalignant skin disease: A randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007;156:320-328. (Pubitemid 46095961)
7. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795-797. (Pubitemid 18094914)
8. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: The case for conservative management. Br J Dermatol. 1986;115:649-655. (Pubitemid 17181888)
9. Green A and Battistutta D. Incidence and determinantsof skin cancer in a high-risk Australian population. Int J Cancer. 1990;46:356-361. (Pubitemid 20291084)
10. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: The case for conservative management. Br J Dermatol. 1986;115:649-655. (Pubitemid 17181888)
11. Neidecker MV, Davis-Ajami ML, Balkrishnan R, et al. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009;27(6):451-464.
12. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995; 32(1):95-98.
13. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42(1 Pt 2):25-28.
14. Lubritz RR and Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982;7:631-632. (Pubitemid 12000529)
15. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Intl J Dermatol. 2004;43:687-692 (Pubitemid 39276301)
16. Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: Phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155:1262-1269. (Pubitemid 44730005)
17. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32(1):63-69.
18. Slaughter DP, Southwick WH, Smejkal W. The multiplicity of origin of malignant tumors: Collective review. Int Abstr Surg. 1944;79:89-98
19. Slaughter DP, Southwick WH, Smejkal W. Field cancerization in oral stratified squamous epithelium; Clinical implications of multicentric origin. Cancer. 1953;6:963-968.
20. Touma D, Yaar M, Whitehead S. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol. 2004;140:33-40. (Pubitemid 38090268)
21. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: A double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5;133-139.
22. Jorizzo J, Weiss J, Furst K. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813-816. (Pubitemid 38917849)
23. Menter A, Vamvakias G, Jorizzo J. One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses. Cutis. 2008;81(6):509-516.
24. Berlin J and Rigel D. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008;7(7):669-673.
25. Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol. 2009;8:35-39.
26. Swanson N, Rosen T, Berman B, et al. 12th World Congress on Cancers of the Skin; May 3-6, 2009; Tel-Aviv, Israel; poster.
27. Green AC, Beardmore GL. Home treatment of skin cancer and solar keratoses. Aust J Dermatol. 1988;29:127-130
28. Ogbounre SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-Ingenyl angelate. Cancer Research. 2004;64:2833-2899.
29. Challacombe JM, Suhrbier A, Parsons PG. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177:8123-8132. (Pubitemid 44846331)
30. Hampson P, Kavanagh D, Smith E, et al. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 2008;57:1241-1251.
31. Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50:16-22.
32. Anderson L, Schmieder G, Werschler P, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934-943.
33. Pariser D, Loss R, Jarratt, M, et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2008;59(4):569-576.